Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Thomas Gurley

Infectious Disease Atlanta, GA Medical Doctor

NPI 1326224635 CMS profile 287372

659 Auburn Ave Ne, Ste 156, Atlanta, GA 30312

Open in the dashboard

General payments

$8,682

482 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Thomas Gurley of Atlanta, GA is reported in the CMS Open Payments database as having received $8,682 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $13 1
2022 General $1,710 78
2021 General $2,619 142
2020 General $2,449 132
2019 General $1,891 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Gurley
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Thomas Gurley were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Thomas Gurley Infectious Disease median Middle half National median
2019 $1,891 $190 $60–$862 $163
2020 $2,449 $124 $32–$606 $114
2021 $2,619 $148 $38–$905 $132
2022 $1,710 $166 $50–$834 $149
2023 $13 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Gilead Sciences, Inc. $1,258 57 payments
  2. ViiV Healthcare Company $1,103 62 payments
  3. Merz North America, Inc. $639 5 payments
  4. Merck Sharp & Dohme Corporation $467 32 payments
  5. Novo Nordisk Inc $444 32 payments
  6. Janssen Biotech, Inc. $421 28 payments
  7. Endo Pharmaceuticals Inc. $383 21 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $330 20 payments
  9. Lilly USA, LLC $327 21 payments
  10. Theratechnologies Inc. $322 19 payments
  11. Other $2,989 185 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,402 471 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $165 9 payments
  3. Education $115 2 payments
Products named General payments · program years 2019–2023
  1. Xeomin $639 5 payments
  2. DOVATO $636 41 payments
  3. SYMTUZA $492 28 payments
  4. AVEED $334 18 payments
  5. XIFAXAN $330 20 payments
  6. EGRIFTA $305 18 payments
  7. CABENUVA $295 10 payments
  8. ASCLERA $292 1 payment
  9. VYVANSE $238 13 payments
  10. TROGARZO $229 13 payments
  11. Other $6,387 426 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record